Zacks Investment Research upgraded shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) from a hold rating to a buy rating in a report issued on Saturday morning. Zacks Investment Research currently has $3.00 target price on the stock.
According to Zacks, “Xenetic Biosciences Inc. is a biopharmaceutical company. It develops biologic drugs, oncology therapeutics and vaccinations. The Company’s proprietary drug technology platforms include PolyXen (R) for the development of next generation biologic drugs and OncoHist (R) for the development of oncology drugs focused on orphan indications. Xenetic Biosciences Inc. based in United States. “
Xenetic Biosciences (XBIO) traded down 6.69% during midday trading on Friday, hitting $2.51. The company had a trading volume of 11,313 shares. The stock’s 50-day moving average price is $2.59 and its 200-day moving average price is $3.33. The stock’s market cap is $21.88 million. Xenetic Biosciences has a 52-week low of $2.30 and a 52-week high of $5.75.
Xenetic Biosciences (NASDAQ:XBIO) last posted its earnings results on Monday, August 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.13). On average, equities research analysts expect that Xenetic Biosciences will post ($0.89) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Xenetic Biosciences, Inc. (XBIO) Upgraded to “Buy” at Zacks Investment Research” was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://transcriptdaily.com/2017/09/17/xenetic-biosciences-inc-xbio-upgraded-to-buy-at-zacks-investment-research.html.
Xenetic Biosciences Company Profile
Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications.
Receive News & Ratings for Xenetic Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.